$XTALPI(02228.HK) The renowned biopharmaceutical media Endpoints has also recognized the transformative impact of AI on the pharmaceutical industry, to the extent that traditional medical commentators can no longer ignore it. As a result, they surveyed 400 readers in the pharmaceutical field and compiled a report. The final conclusion is: AI's current influence is fragmented and fraught with issues—but expectations for the next five years are as absurdly high as a triple-shot morning in Silicon Valley. Pharmaceutical executives and scientists are the most optimistic about AI's prospects, with over 78% of respondents believing AI will revolutionize drug R&D within 3-5 years. The financial sector, however, remains skeptical, with only 53% believing AI will have a significant impact on the pharmaceutical industry by 2030.@Zhou Shuren's Trader@Boss's Boss Dolphin Spokesperson This reveals part of the reason for the volatility of companies like Jingtai in the capital market.